Many researches suggested that GLP-2 and its analogs play a significant role in patients with short bowel syndrome (SBS), including promoting intestinal adaptation, improving the surface area and absorption of the small intestine, and facilitating weaning from parenteral nutrition (23, 24). The gene discussed is GCG; the disease is short bowel syndrome.